Open AccessBrentuximab Vedotin for Refractory Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma in Leukemic Phase with RUNX3 Overexpression
Author(s) -
Yusuke Yamashita,
Yoshikazu Hori,
Hideki Kosako,
Takehiro Oiwa,
Kenji Warigaya,
Toshiki Mushino,
Shogo Murata,
Masakazu Fujimoto,
Akinori Nishikawa,
Shinichi Murata,
Takashi Sawada,
Shinobu Tamura
Publication year - 2020
Publication title -
hematology reports
Language(s) - English
Resource type - Journals
ISSN - 2038-8330
DOI - 10.4081/hr.2020.8368
Subject(s) - anaplastic large cell lymphoma , brentuximab vedotin , medicine , anaplastic lymphoma kinase , lymphoma , cd30 , chop , cancer research , large cell , oncology , pathology , cancer , adenocarcinoma , pleural effusion , malignant pleural effusion
Anaplastic lymphoma kinase (ALK)- negative anaplastic large cell lymphoma (ALCL) is an aggressive CD30-positive non- Hodgkin lymphoma. ALK-ALCL rarely manifests with extensive bone marrow and peripheral blood involvement (known as “leukemic phase”). A 54-year-old woman was diagnosed with ALK-ALCL in leukemic phase, characterized by an extremely poor prognosis. Lymphoma cells in this case showed chromosomal translocation 1p36.1- encoded RUNX3 and overexpression of its protein. She was refractory to CHOP and salvage chemotherapy. Fortunately, she achieved complete remission with three cycles of Brentuximab vedotin (BV) and underwent umbilical cord blood transplantation. However, she died due to treatment-related mortality on day 129. The autopsy findings showed no lymphoma cells. Treatment strategy for ALK-ALCL is controversial, but the efficacy of BV in CD30-positive peripheral T-cell lymphoma not only as salvage regimens, but also in first line, has been reported in recent years. BV may be an effective option for ALK-ALCL in leukemic phase.